Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988138 | 0.77 | FFAR1 (0.65) | RAB9ATP53SMN1; SMN2 | |
| SCHEMBL8008459 | 0.76 | FFAR1 (0.63) | RAB9ATP53SMN1; SMN2 | |
| SCHEMBL4725005 | 0.75 | RAB9A (0.75) | NPC1RAB9ATP53SMN1; SMN2PDE10A | |
| SCHEMBL6800275 | 0.74 | RAB9A (0.69) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL2247920 | 0.74 | RAB9A (1.00) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL5880916 | 0.73 | RAB9A (0.45) | NPC1RAB9AALOX5TP53SMN1; SMN2 | |
| SCHEMBL4763335 | 0.73 | RAB9A (0.67) | NPC1RAB9ATP53SMN1; SMN2PDE10A | |
| SCHEMBL2247503 | 0.73 | RAB9A (0.81) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL4026213 | 0.72 | RAB9A (0.59) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL2245364 | 0.72 | RAB9A (0.78) | NPC1RAB9ATP53SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | NPC1 694/4885RAB9A 3754/4885ALOX5 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.